Clinical Trial Update: Recombinant Human Angioendostatin /PD-1 Mab Combined With First-line Chemotherapy in the Treatment of Driver Gene Negative Advanced NSCLC [Phase 2]

View source ↗

Summary

Phase 2 trial updating a combination of recombinant human endostatin with PD-1 antibody and first-line chemotherapy for driver gene negative advanced non-small …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• Endostatin (endostatin)
• PD-1 mAb (PD-1 monoclonal antibody)

Snippet

Sponsor: Affiliated Cancer Hospital & Institute of Guangzhou Medical University | Conditions: Non Small Cell Lung Cancer, Endostatin | Phase 2 | Status: UNKNOWN